pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Sanofi ($SNY) · news · pharmadog
← back to Sanofi
News mentioning $SNY
221
stories
10h
Big Pharma-backed Nuvig halts development of lead fusion protein in rare autoimmune disease
fiercebiotech
13h
The top biopharma conferences in 2027
biopharma dive
3d
Eli Lilly’s best-ever weight loss data; Sanofi, Regeneron re-up for $1B upfront; and more
endpoints
5d
Sanofi, Regeneron broaden alliance to find their next Dupixent
biopharma dive
5d
Pfizer’s eczema drug clears skin in mid-stage trial
biopharma dive
5d
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
biospace
5d
Sanofi builds on immunology alliance with Regeneron for $1B upfront
endpoints
5d
STAT+: Sanofi, Regeneron expand partnership after Dupixent success
stat
5d
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
fiercebiotech
5d
The top 12 companies hiring in biopharma now
biospace
6d
Recon: Sanofi, Regeneron expand partnership after Dupixent success; Lilly amylin-Zepbound combo succeeds in mid-stage trial
raps
6d
FDA starts review of Roche’s multiple sclerosis pill
biopharma dive
6d
Connect’s Dupixent rival reduces COPD attacks by 85%, but misses a secondary goal
fiercebiotech
7d
Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer
fiercebiotech
7d
Biopharma recruiters see ‘signs of recovery’ as layoffs remain cool in Q3’26
fiercebiotech
8d
6 immunology targets to sustain a mammoth I&I market
biospace
11d
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
biospace
11d
Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil
fiercebiotech
12d
Chutes & Ladders—Travere chief makes way for former Amicus CEO
fiercebiotech
13d
9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe
biopharma dive
13d
Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALS
biospace
13d
9 companies hiring in Pennsylvania now
biospace
14d
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
fiercebiotech
14d
Deep Dive: How AI is now essential in biopharma
biospace
15d
Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
fiercebiotech
18d
Electra lights up with $350M IPO for pivotal immune-disease drug development
biospace
19d
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
19d
North Immunology joins biotech reverse merger boom with Aethlon deal
biopharma dive
19d
Bavarian Nordic names Tarja Stenvall as new CEO
endpoints
19d
North Immunology goes public via reverse merger as eczema drug heads toward clinic
fiercebiotech
← prev
page 1 of 8
next →
